Prostate Cancer Clinical Trial
Official title:
Randomized, Double-blind, Parallel-group, Placebo-controlled, Multi-centre Study to Assess ZD4054 (Zibotentan) in Pain-free or Mildly Symptomatic Patients With Prostate Cancer and Bone Metastases Who Have Rising Serum Prostate Specific Antigen (PSA)
Verified date | January 2013 |
Source | AstraZeneca |
Contact | n/a |
Is FDA regulated | No |
Health authority | United States: Food and Drug Administration |
Study type | Interventional |
This study is being carried out to see if ZD4054 (Zibotentan) is effective in treating prostate cancer and spread of cancer to the bone, and if so, how it compares with placebo (sugar pill). The study will also provide further information on the safety of ZD4054 (Zibotentan).
Status | Completed |
Enrollment | 447 |
Est. completion date | August 2011 |
Est. primary completion date | December 2008 |
Accepts healthy volunteers | No |
Gender | Male |
Age group | 18 Years and older |
Eligibility |
Inclusion Criteria: - Surgically or medically castrated - Bone metastasis - Rising PSA Exclusion Criteria: - Opiate use - Prior chemotherapy |
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment
Country | Name | City | State |
---|---|---|---|
Australia | Research Site | Ashford | South Australia |
Australia | Research Site | Nedlands | |
Australia | Research Site | Wodonga | Victoria |
Australia | Research Site | Wolloongabba | Queensland |
Belgium | Research Site | Brussels | |
Belgium | Research Site | Gent | |
Belgium | Research Site | Leuven | |
Canada | Research site | London | Ontario |
Canada | Research site | Montreal | Quebec |
Canada | Research site | Quebec | |
Canada | Research site | Toronto | Ontario |
Canada | Research site | Vancouver | British Columbia |
Denmark | Research Site | Arhus | |
Denmark | Research Site | Herlev | |
Finland | Research Site | Helsinki | |
Finland | Research Site | Joensuu | |
Finland | Research Site | OYS | |
Finland | Research Site | Seinäjoki | |
Finland | Research Site | Tampere | |
France | Research Site | Lille | |
France | Research Site | Montpellier | |
France | Research Site | Paris | |
France | Research site | Pontoise | |
France | Research Site | Toulouse | |
Indonesia | Research Site | Jakarta | |
Netherlands | Research Site | Eindhoven | |
Netherlands | Research Site | Groningen | |
Netherlands | Research Site | Heerlen | |
Netherlands | Research Site | Leiden | |
Netherlands | Research Site | Rotterdam | |
Netherlands | Research Site | Utrecht | |
Norway | Research Site | Bergen | |
Norway | Research Site | Fredrikstad | |
Norway | Research Site | Moelv | |
Norway | Research Site | Oslo | |
Norway | Research Site | Tonsberg | |
Norway | Research Site | Tromso | |
Norway | Research Site | Trondheim | |
Poland | Research Site | Bydgoszcz | |
Poland | Research Site | Katowice | |
Poland | Research Site | Warszawa | |
Sweden | Research Site | Goteborg | |
Sweden | Research Site | Malmo | |
Sweden | Research Site | Stockholm | |
Switzerland | Research Site | Geneve | |
Switzerland | Research Site | Locarno | |
United Kingdom | Research Site | Birmingham | |
United Kingdom | Research Site | Leeds | |
United Kingdom | Research Site | London | |
United Kingdom | Research Site | Maidstone | |
United Kingdom | Research Site | Manchester | |
United Kingdom | Research Site | Newcastle | |
United Kingdom | Research Site | York | |
United States | Research Site | Baltimore | Maryland |
United States | Research Site | Chicago | Illinois |
United States | Research Site | Cleveland | Ohio |
United States | Research Site | Gainsville | Florida |
United States | Research Site | Los Angeles | California |
United States | Research Site | Simpsonville | South Carolina |
United States | Research Site | Tucson | Arizona |
Lead Sponsor | Collaborator |
---|---|
AstraZeneca |
United States, Australia, Belgium, Canada, Denmark, Finland, France, Indonesia, Netherlands, Norway, Poland, Sweden, Switzerland, United Kingdom,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Time to Progression (TTP) | Median time (in days) from randomisation until disease progression, where progression is defined, using RECIST, as a measurable increase in the smallest dimension of any target or non-target lesion, or the appearance of new lesions, since baseline or death using the Kaplan-Meier method. | Follow-up for progression/death was 4-weekly for 2 years after first dose and 3-monthly thereafter. 'Final analysis' results are given - the most recent formal analysis (data cut-off 18th December 2008). | No |
Secondary | Time to Death | Median time (in days) from randomisation until death using the Kaplan-Meier method. | Follow-up for progression/death was 4-weekly for 2 years after first dose and 3-monthly thereafter. After progression survival was assessed 6-monthly. 'Final analysis' results are given - the most recent formal analysis (data cut-off 18th December 2008). | No |
Secondary | Change in Total Prostate Specific Antigen (PSA) Over Time | Percentage change in total Prostate Specific Antigen (PSA) (ng/mL) from baseline to 12 weeks. | Baseline to 12 weeks. 'Initial analysis' results are given - the most recent formal analysis (data cut-off 10th April 2006). | No |
Secondary | Objective Response Rate (ORR) | Using the Response Evaluation Criteria in Solid Tumours (RECIST), an objective response (OR) is defined as a patient having a best overall response of either complete response (CR) or partial response (PR), which is subsequently confirmed as per RECIST. Objective Response Rate (ORR) is defined as the percentage of patients with OR. | For patients with measurable disease at baseline, Response Evaluation Criteria in Solid Tumours (RECIST) scans were 12-weekly from randomisation. 'Initial analysis' results are given - the most recent formal analysis (data cut-off 10th April 2006). | No |
Secondary | Change in Number of Bone Metastases Over Time | Percentage change in the number of bone metastases from baseline to last available post-baseline scan prior to discontinuation. | Baseline to last available post-baseline scan prior to discontinuation, up to maximum of 1164 days. | No |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05540392 -
An Acupuncture Study for Prostate Cancer Survivors With Urinary Issues
|
Phase 1/Phase 2 | |
Recruiting |
NCT05613023 -
A Trial of 5 Fraction Prostate SBRT Versus 5 Fraction Prostate and Pelvic Nodal SBRT
|
Phase 3 | |
Recruiting |
NCT05156424 -
A Comparison of Aerobic and Resistance Exercise to Counteract Treatment Side Effects in Men With Prostate Cancer
|
Phase 1/Phase 2 | |
Completed |
NCT03177759 -
Living With Prostate Cancer (LPC)
|
||
Completed |
NCT01331083 -
A Phase II Study of PX-866 in Patients With Recurrent or Metastatic Castration Resistant Prostate Cancer
|
Phase 2 | |
Recruiting |
NCT05540782 -
A Study of Cognitive Health in Survivors of Prostate Cancer
|
||
Active, not recruiting |
NCT04742361 -
Efficacy of [18F]PSMA-1007 PET/CT in Patients With Biochemial Recurrent Prostate Cancer
|
Phase 3 | |
Completed |
NCT04400656 -
PROState Pathway Embedded Comparative Trial
|
||
Completed |
NCT02282644 -
Individual Phenotype Analysis in Patients With Castration-Resistant Prostate Cancer With CellSearch® and Flow Cytometry
|
N/A | |
Recruiting |
NCT06305832 -
Salvage Radiotherapy Combined With Androgen Deprivation Therapy (ADT) With or Without Rezvilutamide in the Treatment of Biochemical Recurrence After Radical Prostatectomy for Prostate Cancer
|
Phase 2 | |
Recruiting |
NCT06037954 -
A Study of Mental Health Care in People With Cancer
|
N/A | |
Recruiting |
NCT05761093 -
Patient and Physician Benefit/ Risk Preferences for Treatment of mPC in Hong Kong: a Discrete Choice Experiment
|
||
Completed |
NCT04838626 -
Study of Diagnostic Performance of [18F]CTT1057 for PSMA-positive Tumors Detection
|
Phase 2/Phase 3 | |
Recruiting |
NCT03101176 -
Multiparametric Ultrasound Imaging in Prostate Cancer
|
N/A | |
Completed |
NCT03290417 -
Correlative Analysis of the Genomics of Vitamin D and Omega-3 Fatty Acid Intake in Prostate Cancer
|
N/A | |
Completed |
NCT00341939 -
Retrospective Analysis of a Drug-Metabolizing Genotype in Cancer Patients and Correlation With Pharmacokinetic and Pharmacodynamics Data
|
||
Completed |
NCT01497925 -
Ph 1 Trial of ADI-PEG 20 Plus Docetaxel in Solid Tumors With Emphasis on Prostate Cancer and Non-Small Cell Lung Cancer
|
Phase 1 | |
Recruiting |
NCT03679819 -
Single-center Trial for the Validation of High-resolution Transrectal Ultrasound (Exact Imaging Scanner ExactVu) for the Detection of Prostate Cancer
|
||
Completed |
NCT03554317 -
COMbination of Bipolar Androgen Therapy and Nivolumab
|
Phase 2 | |
Completed |
NCT03271502 -
Effect of Anesthesia on Optic Nerve Sheath Diameter in Patients Undergoing Robot-assisted Laparoscopic Prostatectomy
|
N/A |